Published material on the related Pliva development codes PL-10, PLD-116, and PL-14736 has concentrated on preclinical wound, tissue-protection, and gastrointestinal-injury models rather than randomized human efficacy data, and the peer-reviewed record does not contain a confirmatory efficacy readout for the indications most commonly associated with BPC-157 in informal discussion
Systemic GHK-Cu does different things from locally applied GHK-Cu, and the dose-response curves are different
Reconstituted solutions usually have limited timeframes
Gut health improvements from oral BPC-157 may take several weeks to manifest fully
Injuries to tendons and ligaments can significantly impact daily life, mobility, and performance
American Family Physician